- Wednesday, November 1, 2023
8:00 AM – 8:15 AM ET
Welcome and Introduction
8:00 AM – 8:15 AM ET
Welcome and Introduction
8:15 AM – 8:50 AM ET
Session 1: Updates in Rare Ovarian Cancers (Low Grade, Non-Serous Epithelial and Non-Epithelial)
8:15 AM – 8:50 AM ET
Session 1: Updates in Rare Ovarian Cancers (Low Grade, Non-Serous Epithelial and Non-Epithelial)Presenter: – Levine Cancer Institute at Atrium Health
Wake Forest University School of Medicine
Jubilee Brown, MD (she/her/hers) – Levine Cancer Institute at Atrium Health
Wake Forest University School of Medicine ### 1862807###Presenter###Professor and Division Director of Gynecologic Oncology###Levine Cancer Institute at Atrium Health
Wake Forest University School of Medicine###Presenter: – Levine Cancer Institute at Atrium Health
Wake Forest University School of Medicine
### she/her/hers8:50 AM – 9:00 AM ET
Live Q&A
8:50 AM – 9:00 AM ET
Live Q&AModerator: – Stephenson Cancer Center, University of Oklahoma Health Sciences Center
Presenter: – Levine Cancer Institute at Atrium Health
Wake Forest University School of Medicine
Kathleen N. Moore, MD, MS – Stephenson Cancer Center, University of Oklahoma Health Sciences Center ### 1186885###Moderator###Associate Director of Clinical Research###Stephenson Cancer Center, University of Oklahoma Health Sciences Center###Moderator: – Stephenson Cancer Center, University of Oklahoma Health Sciences Center
### @@@ Jubilee Brown, MD (she/her/hers) – Levine Cancer Institute at Atrium Health
Wake Forest University School of Medicine ### 1862807###Presenter###Professor and Division Director of Gynecologic Oncology###Levine Cancer Institute at Atrium Health
Wake Forest University School of Medicine###Presenter: – Levine Cancer Institute at Atrium Health
Wake Forest University School of Medicine
### she/her/hers9:00 AM – 9:15 AM ET
Break
9:00 AM – 9:15 AM ET
Break
9:15 AM – 10:00 AM ET
Session 2: Assessment and Intervention for Chemotherapy-Induced Neuropathy and Myopathy
9:15 AM – 10:00 AM ET
Session 2: Assessment and Intervention for Chemotherapy-Induced Neuropathy and MyopathyPresenter: – The University of Oklahoma Health Sciences Center/ OU Health Stephenson Cancer Center
Elizabeth Hile, PT, PhD (she/her/hers) – The University of Oklahoma Health Sciences Center/ OU Health Stephenson Cancer Center ### 1862413###Presenter###Associate Professor/ Director of Cancer Rehabilitation Research & Laboratory###The University of Oklahoma Health Sciences Center/ OU Health Stephenson Cancer Center###Presenter: – The University of Oklahoma Health Sciences Center/ OU Health Stephenson Cancer Center
### she/her/hers10:00 AM – 10:15 AM ET
Break
10:00 AM – 10:15 AM ET
Break
10:15 AM – 11:15 AM ET
Non-CME Innovation Theater
10:15 AM – 11:15 AM ET
Non-CME Innovation Theater
11:15 AM – 11:30 AM ET
Break
11:15 AM – 11:30 AM ET
Break
11:30 AM – 12:05 PM ET
Session 3: Management and Challenges of Cervical Cancer Treatment in the Second Line and Beyond
11:30 AM – 12:05 PM ET
Session 3: Management and Challenges of Cervical Cancer Treatment in the Second Line and BeyondPresenter: – Stephenson Cancer Center, University of Oklahoma Health Sciences Center
Debra Richardson, MD (she/her/hers) – Stephenson Cancer Center, University of Oklahoma Health Sciences Center ### 1186893###Presenter###Associate Professor###Stephenson Cancer Center, University of Oklahoma Health Sciences Center###Presenter: – Stephenson Cancer Center, University of Oklahoma Health Sciences Center
### she/her/hers12:05 PM – 12:15 PM ET
Live Q&A
12:05 PM – 12:15 PM ET
Live Q&AModerator: – Stephenson Cancer Center, University of Oklahoma Health Sciences Center
Presenter: – Stephenson Cancer Center, University of Oklahoma Health Sciences Center
Kathleen N. Moore, MD, MS – Stephenson Cancer Center, University of Oklahoma Health Sciences Center ### 1186885###Moderator###Associate Director of Clinical Research###Stephenson Cancer Center, University of Oklahoma Health Sciences Center###Moderator: – Stephenson Cancer Center, University of Oklahoma Health Sciences Center
### @@@ Debra Richardson, MD (she/her/hers) – Stephenson Cancer Center, University of Oklahoma Health Sciences Center ### 1186893###Presenter###Associate Professor###Stephenson Cancer Center, University of Oklahoma Health Sciences Center###Presenter: – Stephenson Cancer Center, University of Oklahoma Health Sciences Center
### she/her/hers12:15 PM – 12:30 PM ET
Break
12:15 PM – 12:30 PM ET
Break
12:30 PM – 1:15 PM ET
Session 4: Endometrial Cancer Treatment Debate: Checkpoint Inhibitors for All vs Individualized Therapies Beyond Checkpoint Inhibitors
12:30 PM – 12:45 PM ET
Session 4: Checkpoint Inhibitors for AllPresenter: – University of California, San Diego
Ramez Eskander, MD – University of California, San Diego ### 1416358###Presenter###Associate Professor###University of California, San Diego###Presenter: – University of California, San Diego
### 12:45 PM – 1:00 PM ET
Session 4: Individualized Checkpoint InhibitorsPresenter: – Director, Principal Investigator, Community Research Development, HonorHealth Research Institute
Bradley Monk, MD – Director, Principal Investigator, Community Research Development, HonorHealth Research Institute ### 1186886###Presenter###Gynecologic Oncologist###Director, Principal Investigator, Community Research Development, HonorHealth Research Institute###Presenter: – Director, Principal Investigator, Community Research Development, HonorHealth Research Institute
### 1:00 PM – 1:15 PM ET
Live Panel DiscussionModerator: – Stephenson Cancer Center, University of Oklahoma Health Sciences Center
Presenter: – Director, Principal Investigator, Community Research Development, HonorHealth Research Institute
Presenter: – University of California, San Diego
Kathleen N. Moore, MD, MS – Stephenson Cancer Center, University of Oklahoma Health Sciences Center ### 1186885###Moderator###Associate Director of Clinical Research###Stephenson Cancer Center, University of Oklahoma Health Sciences Center###Moderator: – Stephenson Cancer Center, University of Oklahoma Health Sciences Center
### @@@ Bradley Monk, MD – Director, Principal Investigator, Community Research Development, HonorHealth Research Institute ### 1186886###Presenter###Gynecologic Oncologist###Director, Principal Investigator, Community Research Development, HonorHealth Research Institute###Presenter: – Director, Principal Investigator, Community Research Development, HonorHealth Research Institute
### @@@ Ramez Eskander, MD – University of California, San Diego ### 1416358###Presenter###Associate Professor###University of California, San Diego###Presenter: – University of California, San Diego
### 1:15 PM – 1:30 PM ET
Break
1:15 PM – 1:30 PM ET
Break
1:30 PM – 2:30 PM ET
Non-CME Innovation Theater
1:30 PM – 2:30 PM ET
Non-CME Innovation Theater
2:30 PM – 2:45 PM ET
Break
2:30 PM – 2:45 PM ET
Break
2:45 PM – 3:20 PM ET
Session 5: Updates in Front Line Adjuvant and Metastatic Treatment of Endometrial Cancer
2:45 PM – 3:20 PM ET
Session 5: Updates in Front Line Adjuvant and Metastatic Treatment of Endometrial Cancer
Matthew Powell, MD (he/him/his) – Washington University School of Medicine ### 1929977###Invited Speaker###Professor and Chief Division Gynecologic Oncology###Washington University School of Medicine###Invited Speaker: – Washington University School of Medicine
### he/him/his3:20 PM – 3:30 PM ET
Live Q&A
3:20 PM – 3:30 PM ET
Live Q&AModerator: – Stephenson Cancer Center, University of Oklahoma Health Sciences Center
Kathleen N. Moore, MD, MS – Stephenson Cancer Center, University of Oklahoma Health Sciences Center ### 1186885###Moderator###Associate Director of Clinical Research###Stephenson Cancer Center, University of Oklahoma Health Sciences Center###Moderator: – Stephenson Cancer Center, University of Oklahoma Health Sciences Center
### @@@ Matthew Powell, MD (he/him/his) – Washington University School of Medicine ### 1929977###Invited Speaker###Professor and Chief Division Gynecologic Oncology###Washington University School of Medicine###Invited Speaker: – Washington University School of Medicine
### he/him/his3:30 PM – 3:45 PM ET
Break
3:30 PM – 3:45 PM ET
Break
3:45 PM – 4:20 PM ET
Session 6: Emerging Developments in Recurrent (2L and beyond) Endometrial Cancer
3:45 PM – 4:20 PM ET
Session 6: Emerging Developments in Recurrent (2L and beyond) Endometrial CancerPresenter: – Stephenson Cancer Center, University of Oklahoma Health Sciences Center
Kathleen N. Moore, MD, MS – Stephenson Cancer Center, University of Oklahoma Health Sciences Center ### 1186885###Presenter###Associate Director of Clinical Research###Stephenson Cancer Center, University of Oklahoma Health Sciences Center###Presenter: – Stephenson Cancer Center, University of Oklahoma Health Sciences Center
### 4:20 PM – 4:30 PM ET
Live Q&A
4:20 PM – 4:30 PM ET
Live Q&A
4:30 PM – 4:45 PM ET
Break
4:30 PM – 4:45 PM ET
Break
4:45 PM – 5:20 PM ET
Session 7: Updates in Molecular Testing and Front-Line Treatment in Ovarian Cancer
4:45 PM – 5:20 PM ET
Session 7: Updates in Molecular Testing and Front-Line Treatment in Ovarian CancerPresenter: – Director, Principal Investigator, Community Research Development, HonorHealth Research Institute
Bradley Monk, MD – Director, Principal Investigator, Community Research Development, HonorHealth Research Institute ### 1186886###Presenter###Gynecologic Oncologist###Director, Principal Investigator, Community Research Development, HonorHealth Research Institute###Presenter: – Director, Principal Investigator, Community Research Development, HonorHealth Research Institute
### 5:20 PM – 5:30 PM ET
Live Q&A
5:20 PM – 5:30 PM ET
Live Q&AModerator: – Stephenson Cancer Center, University of Oklahoma Health Sciences Center
Presenter: – Director, Principal Investigator, Community Research Development, HonorHealth Research Institute
Kathleen N. Moore, MD, MS – Stephenson Cancer Center, University of Oklahoma Health Sciences Center ### 1186885###Moderator###Associate Director of Clinical Research###Stephenson Cancer Center, University of Oklahoma Health Sciences Center###Moderator: – Stephenson Cancer Center, University of Oklahoma Health Sciences Center
### @@@ Bradley Monk, MD – Director, Principal Investigator, Community Research Development, HonorHealth Research Institute ### 1186886###Presenter###Gynecologic Oncologist###Director, Principal Investigator, Community Research Development, HonorHealth Research Institute###Presenter: – Director, Principal Investigator, Community Research Development, HonorHealth Research Institute
###
